PE20141669A1 - Moduladores selectivos del receptor androgeno - Google Patents

Moduladores selectivos del receptor androgeno

Info

Publication number
PE20141669A1
PE20141669A1 PE2014000521A PE2014000521A PE20141669A1 PE 20141669 A1 PE20141669 A1 PE 20141669A1 PE 2014000521 A PE2014000521 A PE 2014000521A PE 2014000521 A PE2014000521 A PE 2014000521A PE 20141669 A1 PE20141669 A1 PE 20141669A1
Authority
PE
Peru
Prior art keywords
methyl
selective androgen
cyclopentil
benzonitrile
chloro
Prior art date
Application number
PE2014000521A
Other languages
English (en)
Spanish (es)
Inventor
Prabhakar Kondaji Jadhav
Ashraf Saeed
Jonathan Edward Green
Venkatesh Krishnan
Donald Paul Matthews
Gregory Alan Stephenson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47046879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141669(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20141669A1 publication Critical patent/PE20141669A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14Nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PE2014000521A 2011-10-13 2012-10-05 Moduladores selectivos del receptor androgeno PE20141669A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161546711P 2011-10-13 2011-10-13

Publications (1)

Publication Number Publication Date
PE20141669A1 true PE20141669A1 (es) 2014-11-08

Family

ID=47046879

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000521A PE20141669A1 (es) 2011-10-13 2012-10-05 Moduladores selectivos del receptor androgeno

Country Status (28)

Country Link
US (1) US8658693B2 (cg-RX-API-DMAC7.html)
EP (1) EP2766350B1 (cg-RX-API-DMAC7.html)
JP (1) JP6002228B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140067102A (cg-RX-API-DMAC7.html)
CN (1) CN103842348B (cg-RX-API-DMAC7.html)
AP (1) AP2014007548A0 (cg-RX-API-DMAC7.html)
AR (1) AR088082A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012321113B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014008668A2 (cg-RX-API-DMAC7.html)
CA (1) CA2847889A1 (cg-RX-API-DMAC7.html)
CL (1) CL2014000895A1 (cg-RX-API-DMAC7.html)
CO (1) CO6910195A2 (cg-RX-API-DMAC7.html)
CR (1) CR20140156A (cg-RX-API-DMAC7.html)
DO (1) DOP2014000075A (cg-RX-API-DMAC7.html)
EA (1) EA201490519A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP14013305A (cg-RX-API-DMAC7.html)
ES (1) ES2626820T3 (cg-RX-API-DMAC7.html)
GT (1) GT201400067A (cg-RX-API-DMAC7.html)
IL (1) IL231440A0 (cg-RX-API-DMAC7.html)
MX (1) MX2014004558A (cg-RX-API-DMAC7.html)
PE (1) PE20141669A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014500808A1 (cg-RX-API-DMAC7.html)
PL (1) PL2766350T3 (cg-RX-API-DMAC7.html)
PT (1) PT2766350T (cg-RX-API-DMAC7.html)
SG (1) SG11201401794YA (cg-RX-API-DMAC7.html)
TN (1) TN2014000136A1 (cg-RX-API-DMAC7.html)
TW (1) TWI449686B (cg-RX-API-DMAC7.html)
WO (1) WO2013055577A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
TW201534586A (zh) * 2013-06-11 2015-09-16 Orion Corp 新穎cyp17抑制劑/抗雄激素劑
EP3077383B1 (en) 2013-12-04 2018-08-22 Evotec International GmbH Sulfoximine substituted quinazolines for pharmaceutical compositions
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
EP3140300B1 (en) 2014-05-07 2019-08-14 Evotec International GmbH Sulfoximine substituted quinazolines for pharmaceutical compositions
CU24522B1 (es) 2016-08-15 2021-06-08 Pfizer PIRIDO[2,3-d]PIRIMIDIN-7(8H)-ONAS 6-FLUOROALQUIL-2-(ALQUILSULFONILPIPERIDIN-4-IL)AMINO SUSTITUIDAS
MA46101B1 (fr) 2016-09-02 2020-10-28 Suven Life Sciences Ltd Modulateurs allostériques positifs du récepteur muscarinique m1
BR112020004441B1 (pt) 2017-09-18 2024-01-16 Basf Se Compostos da fórmula i, composição agroquímica, semente revestida, uso de compostos e método não-terapêutico de combate de fungos
EP4171568B1 (en) * 2020-06-24 2025-08-27 Celgene Corporation Cereblon binding compounds, compositions thereof, and methods of treatment therewith
WO2025104624A1 (en) * 2023-11-14 2025-05-22 Pfizer Inc. Synthesis of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1h-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-d-threo-pentitol

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3594405A (en) * 1968-05-17 1971-07-20 Du Pont Substituted pyranyl anilines as plant growth modifiers
ATE315555T1 (de) * 2001-05-11 2006-02-15 Pfizer Prod Inc Thiazolderivate und ihre verwendung als cdk- inhibitoren
US8519158B2 (en) * 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
PT1891038E (pt) * 2005-05-13 2008-12-02 Lilly Co Eli N-arilpirrolidinas substituídas como moduladores selectivos do receptor de androgénio
ES2384643T3 (es) * 2005-11-30 2012-07-10 Astellas Pharma Inc. Derivados de 2-aminobenzamida como inhibidores del receptor vainilloide 1 (VR1) útiles para el tratamiento del dolor o el trastorno de la función de la vejiga
JP2010524950A (ja) * 2007-04-16 2010-07-22 セレネックス, インコーポレイテッド テトラヒドロインドールおよびテトラヒドロインダゾール誘導体
CN101828200A (zh) * 2007-10-19 2010-09-08 米歇尔·勒唐德尔-赫德伦 标识环境友好企业或个人的方法
ES2488990T3 (es) * 2008-02-22 2014-09-01 Radius Health, Inc. Moduladores selectivos del receptor de andrógenos

Also Published As

Publication number Publication date
SG11201401794YA (en) 2014-09-26
AU2012321113A1 (en) 2014-03-27
AP2014007548A0 (en) 2014-03-31
PL2766350T3 (pl) 2017-08-31
ECSP14013305A (es) 2014-05-31
CL2014000895A1 (es) 2014-08-22
CR20140156A (es) 2014-05-16
US20130217762A1 (en) 2013-08-22
EA201490519A1 (ru) 2014-09-30
JP6002228B2 (ja) 2016-10-05
TW201329026A (zh) 2013-07-16
MX2014004558A (es) 2014-08-01
EP2766350A1 (en) 2014-08-20
ES2626820T3 (es) 2017-07-26
US8658693B2 (en) 2014-02-25
PT2766350T (pt) 2017-05-22
AR088082A1 (es) 2014-05-07
TWI449686B (zh) 2014-08-21
TN2014000136A1 (en) 2015-07-01
WO2013055577A1 (en) 2013-04-18
BR112014008668A2 (pt) 2017-04-25
PH12014500808A1 (en) 2019-07-03
DOP2014000075A (es) 2014-06-01
EP2766350B1 (en) 2017-04-05
CA2847889A1 (en) 2013-04-18
JP2014530818A (ja) 2014-11-20
CN103842348B (zh) 2015-08-19
IL231440A0 (en) 2014-04-30
CN103842348A (zh) 2014-06-04
CO6910195A2 (es) 2014-03-31
AU2012321113B2 (en) 2015-07-09
GT201400067A (es) 2015-02-27
KR20140067102A (ko) 2014-06-03

Similar Documents

Publication Publication Date Title
PE20141669A1 (es) Moduladores selectivos del receptor androgeno
AR125013A2 (es) Método para mejorar la solubilidad de una sustancia que es 9-etil-6,6-dimetil-8-(4-morfolin-4-il-piperidin-1-il)-11-oxo-6,11-dihidro-5h-benzo[b]carbazol-3-carbonitrilo o una sal del mismo
EA201170676A1 (ru) Агонисты рецептора меланокортина
RU2008139315A (ru) Избирательные андрогенные рецепторные модуляторы
EA201590200A1 (ru) Модуляторы пути активации комплемента и их применение
EA201001724A1 (ru) Производные изоксазола и их применение в качестве потенциирующих средств для метаботропных глутаматных рецепторов
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
TN2014000030A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
EA201590118A1 (ru) Производные пирролидина и их применение в качестве модуляторов пути активации комплемента
CR20160212A (es) Composiciones y métodos para modular los receptores x farnesoides
CO2022010305A2 (es) Método y aplicación de preparación de compuesto como agente de degradación de proteínas
CL2011000558A1 (es) Formas cristalinas de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; sal de sodio del compuesto, composicion farmaceutica que comprende la sal de sodio, util para tratar una infeccion por el virus de la hepatitis c.
HN2012001351A (es) Derivados de 3- hidroxi-5-arilisotiazol novedosos
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
EA201190021A1 (ru) Модуляторы toll-подобных рецепторов
DOP2013000181A (es) Moduladores del receptor de glucagon
PE20160996A1 (es) Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp
EA201390843A1 (ru) Применение агониста toll-подобного рецептора для лечения рака
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
UY33815A (es) Composiciones y métodos para modular el fxr
UY31863A (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
EA201291476A1 (ru) Комбинации, содержащие атипичные антипсихотические средства и агонисты taar1
EA201391525A1 (ru) Гликозидные производные и их применение для лечения диабета
EA201591815A1 (ru) Бицикло [2.2.2] кислоты - модуляторы gpr120
AR088297A1 (es) R(+)-n-formil-propargil-aminoindano

Legal Events

Date Code Title Description
FD Application declared void or lapsed